Gliclazide Capsules

This product is a second-generation sulfonylurea hypoglycemic drug with a strong effect. Its mechanism is to selectively act on pancreatic islet b cells, promote insulin secretion, and increase insulin release after eating glucose, so that the production and output of glycogen are inhibited. This product has been proven through animal experiments and clinical use to reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy.

Gliclazide.

Type 2 diabetes.

The initial oral dose is 40-80 mg, 1-2 times a day, and then adjusted to 80-240 mg a day, divided into 2-3 doses, depending on the blood sugar level. After blood sugar is controlled, the daily maintenance dose can be changed. Elderly patients can reduce the dose as appropriate.

Most patients tolerate this product well. The most common side effects are gastrointestinal symptoms, such as abdominal pain, nausea, dizziness and rash. Hypoglycemia occurs rarely and is mild.

1. Patients with impaired liver and kidney function are prohibited from using this product. 2. Patients who are allergic to sulfonylurea drugs are prohibited from using this product.

When used in combination with non-steroidal anti-inflammatory drugs (especially salicylates), sulfonamide antibiotics, coumarin anticoagulants, monoamine oxidase inhibitors, b-receptor blockers, benzodiazepines, tetracycline, chloramphenicol, dicyclohexine, clofibrate, ethanol and other drugs, the dosage should be reduced to avoid hypoglycemia.

Keep away from light and store in a sealed container.

40mg

Guangxi Changhong Pharmaceutical Co., Ltd.

• Founded in:

  1993-01-09

• Address:

  No. 68, Jianye Road, Liangqing District, Nanning City, Guangxi

• Tax NO.:

  914500006193013418

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view